The company plans to initiate two registrational studies for NDV-01 and a Phase II sepranolone study in the first half of 2026. Traversa also spotlighted the hiring of Dr. Raj Pruthi as Chief Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback